Digest Network Come funziona
Network
/
Società
Ba
Non verificato

Basilea Pharmaceutica International Ltd, Allschwil

Di cosa scriviamo

Annunci EconomiciBiotecnologiaMedicina Salute BenesserePolitica InternazionalePubblicità/Marketing/Media/Comunicazione

13 comunicati stampa

Guarda tutti i comunicati
26/10/2026
Biotecnologia
Annunci Economici
Politica Internazionale
Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
19/10/2026
Biotecnologia
Pubblicità/Marketing/Media/Comunicazione
Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
13/09/2026
Biotecnologia
Annunci Economici
Medicina Salute Benessere
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
17/08/2026
Biotecnologia
Annunci Economici
Politica Internazionale
Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
04/08/2026
Biotecnologia
Medicina Salute Benessere
Politica Internazionale
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
28/07/2026
Biotecnologia
Medicina Salute Benessere
Politica Internazionale
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
27/05/2026
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Politica Internazionale
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
15/04/2026
Biotecnologia
Annunci Economici
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
08/04/2026
Biotecnologia
Annunci Economici
Politica Internazionale
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0
22/03/2026
Biotecnologia
Annunci Economici
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Fonte
Basilea Pharmaceutica International Ltd, Allschwil
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0